Likewise, the FGFR2-specific degrader N5, generated by coupling erdafitinib to a CRBN ligand, achieves exceptional FGFR2 degradation (DC50 = 0.03 nmol/L) with minimal off-target activity, and exerts strong antiproliferative effects in FGFR2-amplified gastric cancer cells and xenografts.233. The gene discussed is FGFR2; the disease is gastric cancer.